Feature Summary:

EchinaMed is the result of a highly sophisticated, patented extraction process that guarantees consistent levels of Echinacea purpurea’s three key active constituents – alkylamides, polysaccharides and cichoric acid. These active constituents are provided in a base of whole herb, so that none of the minor actives are missing. EchinaMed is the first echinacea extract that meets the rigorous scientific standards demanded of pharmaceuticals. It is the only extract tested in two randomized, double-blind, placebo controlled phase II clinical trials. These trials, as well as laboratory evidence, have demonstrated that EchinaMed is an effective stimulant of the innate immune system reducing the severity and duration of upper respiratory tract infections, and possibly mitigating the risk of secondary infections. EchinaMed has been found to increase the number of circulating white blood cells, monocytes, neutrophils and natural killer cells. In vivo animal studies have demonstrated an increase in alveolar macrophage phagocytic response in a dose-dependent manner, as well as increased nitric oxide and tumour necrosis factor alpha (TNF-α). Nitric oxide is one of the primary mechanisms by which alveolar macrophages destroy foreign particles in the lungs, while TNF-α has antiviral effects, accounting for EchinaMed’s ability to act both therapeutically and preventatively.